![Patrick Fabbio](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick Fabbio
Finanzdirektor/CFO bei PROTARA THERAPEUTICS, INC.
Vermögen: 141 390 $ am 31.05.2024
Profil
Patrick Fabbio is currently an Independent Director at BeyondSpring, Inc. and the Chief Financial Officer at Protara Therapeutics, Inc. Previously, he held positions as Vice President-Finance at NPS Pharmaceuticals, Inc. from 2012 to 2015, Controller at Biomatrix, Inc., Chief Financial Officer, Secretary & Senior VP at Progenics Pharmaceuticals, Inc. from 2015 to 2020, Chief Financial Officer at Ikano Therapeutics, Inc. from 2009 to 2011, Auditor at Coopers & Lybrand (London), Vice President-Finance, Innovation & Growth at Catalent Pharma Solutions, Inc., and Chief Financial Officer at electroCore, Inc. He also served as the Chief Financial Officer at WindMIL Therapeutics, Inc. from 2020 to 2021 and as the Chief Financial & Accounting Officer at Rafael Holdings, Inc. in 2023.
Mr. Fabbio obtained an undergraduate degree from Pace University and an MBA from The Leonard N Stern School of Business.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
17.11.2023 | 50 139 ( 0,21% ) | 76 713 $ | 31.05.2024 | |
BEYONDSPRING INC.
0,06% | 01.04.2024 | 24 592 ( 0,06% ) | 64 677 $ | 31.05.2024 |
11.04.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Patrick Fabbio
Unternehmen | Position | Beginn |
---|---|---|
BEYONDSPRING INC. | Direktor/Vorstandsmitglied | 02.01.2018 |
PROTARA THERAPEUTICS, INC. | Finanzdirektor/CFO | 30.01.2023 |
Ehemalige bekannte Positionen von Patrick Fabbio
Unternehmen | Position | Ende |
---|---|---|
RAFAEL HOLDINGS, INC. | Präsident | 01.01.2023 |
WindMIL Therapeutics, Inc.
![]() WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Finanzdirektor/CFO | 01.09.2021 |
PROGENICS PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 27.03.2020 |
NPS PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 01.05.2015 |
Ikano Therapeutics, Inc.
![]() Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | Finanzdirektor/CFO | 18.01.2011 |
Ausbildung von Patrick Fabbio
Pace University | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ELECTROCORE, INC. | Health Technology |
BEYONDSPRING INC. | Health Technology |
RAFAEL HOLDINGS, INC. | Finance |
PROTARA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Ikano Therapeutics, Inc.
![]() Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | Health Technology |
Biomatrix, Inc.
![]() Biomatrix, Inc. Pharmaceuticals: MajorHealth Technology Biomatrix, Inc. develops, manufactures, markets and sells a series of proprietary viscoelastic products called 'hylans'. Hylans are the second generation of viscoelastics used in medicine and are characterized by significantly enhanced physical properties such as elasticity, viscosity and pseudoplasticity. These products are used in therapeutic medical applications and skin care. The company was founded by Endre A. Balazs and Janet L. Denlinger in 1981 and is headquartered in Ridgefield, NJ. | Health Technology |
Coopers & Lybrand (London)
![]() Coopers & Lybrand (London) Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand (London) is a British company that provides accounting services. The company is based in Edinburgh, UK. | Commercial Services |
Progenics Pharmaceuticals, Inc.
![]() Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
NPS Pharmaceuticals, Inc.
![]() NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Catalent Pharma Solutions, Inc.
![]() Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
WindMIL Therapeutics, Inc.
![]() WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Health Technology |